Poor interrater reliability of hidradenitis suppurativa phenotypes
To the Editor: Hidradenitis suppurativa (HS) is a chronic, recurrent, debilitating inflammatory skin disease. The clinical presentation of HS is heterogeneous, and therefore, different phenotypes are thought to exist. Different phenotypes could differ in etiology and prognosis and could potentially require different treatment strategies. 1 In 2013, Canoui-Poitrine et al were the first to propose phenotypes and identified 3 phenotypes on the basis of latent class analysis of a database containing 618 HS patients. 2 For detailed characteristics of the 3 identified phenotypes (axillary-mammary type, follicular type, and gluteal type) see Table I . The Canoui-Poitrine phenotypes have not been validated in clinical practice or used in clinical trials. Therefore, the aim of this study was to evaluate their interrater reliability in a clinical setting.
In 2017, thirty real-life cases were randomly selected from the population seen at the Department of Dermatology, Erasmus Medical Center, Rotterdam, The Netherlands, during March 2016-July 2017. Subsequently, the 30 cases were anonymized and digitalized by an author (Verhagen), who did not participate in the scoring of the cases. The following parameters, which were required to distinguish the 3 proposed phenotypes, were presented digitally: lesion types (hypertrophic scars, epidermal cysts, comedones papules, folliculitis); affected areas; disease duration; Hurley staging; sex; co-morbidities ( pilonidal sinus, acne); smoking status; and body mass index.
A panel of 8 Dutch HS experts (5 dermatologists and 3 graduate students with extensive clinical experience with HS) were supplied with detailed information on the Canoui-Poitrine phenotypes. All experts, independently and without conferring, assigned a phenotype to each of these digital cases. The Guidelines for Reporting Reliability and Agreement Studies were used as a basis for the design and documentation of this interrater reliability study. 3 The interrater reliability was calculated as a Fleiss' kappa. For the interpretation of the kappa values, the benchmarks proposed by Landis and Koch were used. 4 For this type of investigation, no medical ethical committee approval is required under Dutch law.
The assessors agreed on the same Canoui-Poitrine phenotype for only 23.3% of cases, and the phenotypes reached a of 0.37 (95% confidence interval 0.32-0.42), indicating slight interrater reliability (Fig 1) . Canoui-Poitrine et al stated that their classification is legitimate, as the phenotypes fit with typical and atypical clinical observations. However, in our view, while subtyping HS patients by CanouiPoitrine phenotype might be useful at a population level, it does not appear to be applicable at the individual level in daily practice. In our experience, characteristics from [1 phenotype are often present in the same patient, restricting straightforward classification. An effort to divide HS patients into clinical subtypes has been performed by van der Zee et al. 5 However, these phenotypes are yet to be evaluated.
In summary, the HS phenotypes proposed by Canoui-Poitrine et al reached only slight interrater reliability. We, therefore, conclude that CanouiPoitrine phenotypes are of limited use in clinical practice and research setting. Therefore a new subset of HS phenotypes is required. 
